Literature DB >> 8244252

Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection.

M Kurosaki1, N Enomoto, F Marumo, C Sato.   

Abstract

To evaluate the clinical significance of sequence variations in the hypervariable region of hepatitis C virus during the course of chronic infection, we performed pairwise comparison of the predominant nucleotide sequences. Hepatitis C virus RNA was extracted from two plasma samples obtained from 12 chronically infected Japanese patients over approximately 1 yr. Complementary DNA containing the hypervariable region was amplified by means of reverse transcription-polymerase chain reaction and was directly sequenced for determination of predominant sequences. In all 12 individuals, the predominant sequence of the hypervariable region at the second time point differed from that at the first time point, and significant sequence variation was observed during this short period. A high proportion of these nucleotide substitutions (90%) resulted in changes of predicted amino acid sequences, indirect evidence of in vivo positive selection for these variants. There appeared to be an important difference in the rate of nucleotide sequence variation of the hypervariable region between four patients with flare-ups of their ALT levels (1.54 to 2.24 x 10(-1)/genome site/yr) and eight patients with quiescent courses (0.13 to 1.21 x 10(-1)/genome site/yr). These results demonstrate that rapid sequence variations of the hypervariable region of predominant virus population take place during the natural course of chronic hepatitis C virus infection. These sequence variations seem to occur as an adaptive response of hepatitis C virus to evade host immunity and may play a major role in the establishment of persistent infection and in the occasional flare-up of hepatitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244252

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

1.  Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome.

Authors:  Catherine Gaudy; Alain Moreau; Pascal Veillon; Stephanie Temoin; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

2.  Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing.

Authors:  Michael Lauck; Mónica V Alvarado-Mora; Ericka A Becker; Dipankar Bhattacharya; Rob Striker; Austin L Hughes; Flair J Carrilho; David H O'Connor; João R Rebello Pinho
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

3.  Functional analysis of hepatitis C virus envelope proteins, using a cell-cell fusion assay.

Authors:  Mariko Kobayashi; Michael C Bennett; Theodore Bercot; Ila R Singh
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Anti-envelope antibodies in anti-hepatitis C virus (HCV) positive patients with and without liver disease.

Authors:  M Pirisi; P Ferroni; C Fabris; P Toniutto; G Soardo; D Vitulli; V Gasparini; E Bartoli
Journal:  Infection       Date:  1995 Jan-Feb       Impact factor: 3.553

Review 5.  [Therapy of hepatitis C].

Authors:  D M Alscher; J C Bode
Journal:  Med Klin (Munich)       Date:  1997-03-15

Review 6.  The quasispecies of hepatitis C virus and the host immune response.

Authors:  P Farci; J Bukh; R H Purcell
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Predictors of response to interferon therapy.

Authors:  G Saracco; M Rizzetto
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

8.  Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity.

Authors:  Javier Fernandez; Deborah Taylor; Duncan R Morhardt; Kathleen Mihalik; Montserrat Puig; Charles M Rice; Stephen M Feinstone; Marian E Major
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.

Authors:  Hui Li; Brian J McMahon; Susan McArdle; Dana Bruden; Daniel G Sullivan; Dave Shelton; Heike Deubner; David R Gretch
Journal:  Virology       Date:  2008-03-17       Impact factor: 3.616

10.  Efficacy of combination therapy with interferon and azidothymidine in chronic type C hepatitis: a pilot study.

Authors:  M Tsutsumi; A Takada; M Sawada
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.